Pelthos Therapeutics’ Post

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

The year is nearly over, and it is time to reflect on the events of the past 12 months. Take a look at our latest blog post to get an overview of Senorics’ highlights of 2023. We wish you a great start into the new year! 🎇🥂 #materialsensing #NIR #team #review #blog #happynewyear

Spherix Global Insights Appoints Dan Barton CEO - https://lnkd.in/gUKMic9m Follow #citybiz on LinkedIn - https://lnkd.in/eBgXKiz8 Spherix Global Insights

A first step in our M&A journey to strengthen our existing and best-in-class tides platform 🔥🔥🔥🔥

Check out this webinar with Chris Dokomajilar on January 16th to see what the year may look like for biopharma dealmaking in 2024! #venturecapital #biotech #biopharma #pharma #dealmaking #2024predictions

Following our recent acquisition of Reach Separations, here’s what Peter Ridgway, Business Development Director at Reach Separations, had to say: "Becoming part of the CatSci Ltd Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces." This strategic acquisition marks a significant milestone for CatSci and enhances our ability to deliver programmes where rapid purification by chromatography is often essential to expediting clinical development. Together with Reach, we will drive forward our shared mission to deliver excellence in medicines development.   Learn more about how this acquisition will solve our customers' separation science challenges: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

Ziccum had an intensive schedule of meetings at Nordic Life Science Copenhagen Nov 29–30. CEO Ann Gidner and Chairman Fredrik Sjövall were invited to partnering meetings with new interested prospects and attended valuable follow-up meetings. CEO: ‘the knowledge of our offering is high and we expect to pursue many dialogues initiated here. It’s very satisfying we could move dialogues to a more strategic level with large corporation counterparts. We’d like to thank our industry colleagues for an engaging, well-attended event” https://lnkd.in/dq4pff64 #nlsdays #biologics #biopharmaceuticals #formulatiion #vaccines #thermostablevaccines

Whilst its been a tough year thus far, its great to see some positive news regarding investment into the clinical research sector! PE firm Permira, who already have some big CDMO names in their healthcare portfolio with the likes of Quotient Sciences and Cambrex to name a few, seem to be diversifying and adding CRO capabilities with the acquisition of ERGOMED for a whopping £703M...could we potentially see a merger in the future to create a 'one stop shop'? Either way there are exciting times ahead for Ergomed, lets watch this space. #mergersandacquisitions #cro #cmo #cmlifescience #clinicalresearch #clinicaltrials #growth #ergomed #permira

WSB Investor Call | June 21, 2022 (Preview) Here's a preview of the investor call with David Maris and Sarepta Therapeutics CEO Douglas S. Ingram. Whether you own $SRPT or thinking of getting long, you can't miss this discussion. "Our goal here is to delve deeper into the implications of the approval and understand Sarepta's longer term objectives." - David Maris "This is an enormous moment for the company." - Doug Ingram Access the entire Investor Call on $SRPT and don't miss Doug's incredible insights near the end on the importance of corporate culture in his organizations. Click the link in the comments sections to access. Fantastic discussion gentlemen! #InvestSmarter

Fantastic series B fund raise to close out 2023! Exciting 2024 ahead for everyone at Sudo Biosciences as they take two of their best/first in class, next gen TYK2 inhibitors into clinic. #fundraise #researchanddevelopment #lifesciences #biotechnology #neurology #dermatology